The free dividend tracker to help you grow your wealth. Link your brokerage accounts and MerryDiv automatically syncs your holdings and dividends.
Data last updated: Aug 31, 2026
Snapshot (as of Aug 31, 2026): Novo Nordisk A/S (NVO) pays a $7.50 annual dividend ($0.58 monthly), yielding 2.55% at $45.61/share. Next ex-dividend date 2026-08-17. 8 consecutive years of dividend growth. Source: Yahoo Finance, aggregated by MerryDiv.
Dividend Yield: 2.55%
Annual Dividend: $7.50 per share
Payout Ratio: 44.6%
Ex-Dividend Date: 2026-08-17
Dividend Frequency: monthly
Sector: Healthcare
Years of Dividend History: 45
Novo Nordisk A/S dividend investors are buying into one of the world's largest pharmaceutical companies, built around diabetes and obesity therapies, rare blood disorders, and devices like insulin pens. NVO currently pays a 2.55% dividend yield. The trailing annual dividend rate is $7.50 per share, paid monthly, with the next ex-dividend date on August 17, 2026. A beta of 0.349 means NVO stock moves far less than the broader market, which suits income investors who prioritize low volatility over maximum yield.
Novo Nordisk A/S pays out 44.6% of earnings as dividends, a payout ratio classified as moderate (40–60%). That level leaves meaningful earnings retained within the business, and NVO's two core divisions, Diabetes and Obesity Care and Rare Disease, address chronic conditions that generate recurring demand for therapies and devices. Novo Nordisk A/S dividend safety faces its most visible pressure from currency exposure: the company operates across Europe, North America, Asia, and the Middle East, meaning that a strengthening Danish krone or U.S. dollar swings can affect the per-share dollar amounts paid to international holders.
Novo Nordisk A/S dividend history shows a CAGR of 18.0% per year from 2010 to 2025. Per-share payments grew from $0.1407 to $1.6830 over that window (2026 is a partial year and excluded from the CAGR calculation). The largest single-year jump in the window was 85.7% in 2016, though the data also contains at least one year-over-year decline exceeding 5%, so the path has not been linear.
| Period | CAGR | From | To |
|---|---|---|---|
| 3-Year | +27.6% | $0.81 (2022) | $1.68 (2025) |
| 5-Year | +20.9% | $0.65 (2020) | $1.68 (2025) |
| 10-Year | +16.0% | $0.38 (2015) | $1.68 (2025) |
NVO fits dividend investors who want meaningful income growth from a pharmaceutical business anchored in chronic-disease therapies. The current yield of 2.55% is moderate (2–4%), and it sits below the 5-year average yield of 3.64%, meaning buyers today are paying a higher price relative to the dividend than the historical norm. Eight consecutive years of dividend increases back the growth story, and an 18.0% CAGR over 15 years is genuinely fast for a healthcare payer. The trade-off is a yield that has compressed as the share price has risen, so income investors accept a lower starting yield in exchange for a dividend that has historically grown at an exceptional pace.
| Payment Date | Amount per Share |
|---|---|
| 2026-08-17 | $0.5786 |
| 2026-03-30 | $1.2174 |
| 2025-08-18 | $0.5840 |
| 2025-03-31 | $1.0990 |
| 2024-08-16 | $0.5130 |
| 2024-03-22 | $0.9300 |
| 2023-08-18 | $0.4420 |
| 2023-03-24 | $0.5945 |
| 2022-08-12 | $0.2920 |
| 2022-03-25 | $0.5180 |
| Year | Total Dividends |
|---|---|
| 2026 | $1.7960 |
| 2025 | $1.6830 |
| 2024 | $1.4430 |
| 2023 | $1.0365 |
| 2022 | $0.8100 |
Project income from NVO with the NVO dividend calculator or track your full portfolio with the dividend tracker.